Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models|
|Citation:||Cancer Letters, 2013; 339(1):42-48|
|Publisher:||Elsevier Sci Ireland Ltd|
|Ke-Wang Luo, Chun-Hay Ko, Grace G.L. Yue, Michelle Y.Y. Lee, Wing-Sum Siu, Julia K.M. Lee, Wai-Ting Shum, Kwok-Pui Fung, Ping-Chung Leung, Gang Li, Andreas Evdokiou, Clara B.S. Lau|
|Abstract:||This study aims to determine the effect of metronomic (0.0125 mg/kg twice a week for 4 weeks) zoledronic acid (ZOL) on cancer propagation and osteolysis against both metastatic and primary breast cancer in mice model. From our results, metronomic ZOL resulted in a significant reduction of tumor burden and did not promote lung or liver metastasis. The metronomic ZOL appeared to be more effective than the conventional regimen (0.1 mg/kg once in 4 weeks) in reducing breast cancer tumor burden, and regulating its movement to lung and liver. This dosing schedule of ZOL showed great potential against metastatic breast cancer.|
|Keywords:||Zoledronic acid; Metronomic; Conventional; Anti-osteolysis; Metastasis|
|Rights:||Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.|
|Appears in Collections:||Orthopaedics and Trauma publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.